GSK3B and early-onset autosomal dominant Alzheimer disease: In the recent decade small molecule inhibitors of GSK-3β are emerging as a promising drug for treatments against neurodegenerative diseases, radiation damage, Alzheimer's disease, diabetes, and cancer [116].